Peroxisome proliferator-activated receptor g (PPARg) is a nuclear receptor having a key role in adipogenesis [1] . The PPARg has been identified as the receptor for the thiazolidinediones, a new class of oral antidiabetic agents which improves glycaemic control by lowering peripheral insulin resistance.
served in various tissues but has not been described in the human pancreas [6] . Therefore the goal of this study is to examine the expression of PPARg at the mRNA and protein levels in normal human endocrine pancreatic cells.
Materials and methods
Materials. Rosiglitazone (BRL-49,653) was a gift from Dr R. Heyman at Ligand Pharmaceuticals (San Diego, Calif., USA).
Human tissues. Human pancreata (n = 10) were procured from brain-dead non-diabetic (mean HbA 1C = 5.4 0.1) and nonobese (mean BMI = 27 1) adult donors (mean age 41.3 3.5) in accordance with French regulations. Pancreata were stored at 4 C in Euro-Collins solution (Fresenius, Bad Homburg, Germany) until islets were isolated with the semiautomatic method of Ricordi and purified with Euroficoll (Ficoll 400 DL, Sigma Aldrich, Saint Quentin Fallavier, France) or Histopaque (Sigma Aldrich) discontinuous density gradients following a multilayer test gradient. Purity of preparations was visually estimated, usually as greater than 80 % after staining islets with dithizone. Islet preparations were cultured in CMRL-1066 (Gibco BRL, Paisley, Scotland) supplemented with 2 % Ultroser G (Gibco BRL), 100 UI/ml penicillin, 100 mg/ml streptomycin, 50 mg/ml gentamycin and 1 mg/ml amphoterycin B. Mesenteric white adipose tissues (WAT) and colon biopsy specimens obtained during surgery from non-diabetic and non-obese patients were included as control for RNA and protein analysis. All tissues samples were immediately frozen in liquid nitrogen.
Antibodies. The PPARg antibody used in this study was a polyclonal IgG developed against a peptide corresponding to amino acids 20±104 of human PPARg. This antibody was highly specific for PPARg and did not cross-react with PPARa or b as described previously [7] . Antibodies to islet specific hormones included polyclonal and monoclonal anti-insulin (BioGenex, Paris, France) and polyclonal anti-glucagon and antisomatostatin (Dako, Carpinteria, Calif., USA).
Western blot analysis. Total protein from islet preparations (n = 5), mesenteric WAT (n = 2) and colon (n = 2) were obtained by homogenisation in extraction buffer composed of Triton (2 %) to which a protease inhibitor cocktail was added [7] . Separation of total proteins (50 mg per lane), transfer to nitro-cellulose membranes and immunodetection of PPARg were done as described [7] . The complex was revealed by chemiluminescence according to the manufacturer's protocol (ECL; Amersham Life Science, Les Ulis, France).
mRNA analysis by RT-competitive PCR. Total RNA from islet preparations (n = 4), mesenteric WAT (n = 9) and colon (n = 18) were extracted using Tri-reagent (Euromedex, Souffelweyersheim, France) according to the manufacturer's instructions. First strand cDNA was generated from total RNA and PPARg and b-actin cDNA were amplified by 40 competitive PCR cycles as described [8] .
Immunohistochemistry. Pancreas samples (n = 5) were fixed for 18 h in 4 % paraformaldehyde, embedded in paraffin and sectioned (5 mm). After deparaffinisation and rehydration in ethanol, non-specific binding and endogenous peroxidases were blocked with 10 % goat serum and hydrogen peroxidase, respectively, when necessary. All antibodies were incubated 1 h at room temperature with the following dilutions 1/50 for anti-PPARg, 1/100 for polyclonal anti-insulin, 1/750 for monoclonal anti-insulin, 1/400 for anti-glucagon and 1/500 for anti-somatostatin. For simple immunolabelling on adjacent sections, primary antibodies were revealed with the streptavidin-biotin-peroxidase system (HistoMark kit; Kirkegaard and Perry Laboratories, Gaithersburg, Md., USA) using the chromogen 3-amino-9-ethyl-carbazole (AEC; Sigma Aldrich). In double immunolabelling procedures, antiPPARg polyclonal antibody was visualised with the EnVision phosphatase mouse/rabbit kit (Dako) using the chromogen 5-bromo-4-chloro-3-indoxyl phosphatase / nitro blue tetrazolium chloride (BCIP/NBT; Dako) and anti-insulin monoclonal antibody with the Envision peroxidase mouse using AEC. Control sections were incubated with dilution buffer (PBS with 1 % BSA) instead of the primary antibody. In some sections nuclei were counterstained with Carazzi's haematoxylin.
In vitro insulin secretion. Rosiglitazone was dissolved in dimethyl sulphoxide (DMSO). After a 24-h culture, random samples of islet preparations containing 40 islets with an equivalent diameter of 150 mm were distributed in 96-well multiscreen assay system (Millipore, Strasbourg, France) [9] and cultured for 48 h in fresh medium supplemented with rosiglitazone (10 ±8 , 10 ±7 , 10 ±6 or 10 ±5 mol/l) or DMSO for controls. After a 48-h culture, a static incubation was done that consisted of a preincubation for 90 min (with 3.3 mmol/l glucose), followed by three incubations of 1 h with 3.3 mmol/l glucose (basal 1), 16.6 mmol/l glucose + 0.1 mmol/l 3-isobutyl-1-methylxanthine (IBMX) (stimulation) and 3.3 mmol/l glucose (basal 2), respectively, in KRB containing 0.5 % BSA. At the end of each incubation, KRB was collected. All samples were frozen at ±20 C until insulin secretion was evaluated (bi-insulin IRMA, Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France). Basal insulin secretion was defined as the mean of basal 1 and basal 2 secretions. For each condition, the mean result of six experiments for each of three distinct islet preparations was considered.
Statistical analyses. Continuous variables are expressed as means SEM. Statistical analysis of insulin secretion values was by the ANOVA test (StatView, Abacus Concept, Berkeley, Calif., USA). Significance was set at p < 0.05.
Results
Expression of PPARg protein and mRNA in the human pancreas. The expression of human PPARg protein was analysed in human islet preparations and compared with other tissues expressing PPARg protein. Western blot analysis of lysates of mesenteric WAT and colon revealed a band with an approximate molecular mass of 53,000 Mr, corresponding to the molecular weight of PPARg (Fig. 1) . Notably, lysates of islet preparations revealed a slightly higher band of approximately 55,000 Mr, most likely corresponding to a phosphorylated form of PPARg. Expression of PPARg in islets was approximately 2/3 of those detected in mesenteric WAT (Fig. 1) . Expression of PPARg remained unchanged in islets after 8 days of culture (data not shown). The RT-PCR confirmed the presence of PPARg mRNA (product size 475 bp) in all islet preparations (Fig. 1) , cDNA molecules in the mesenteric WAT (n = 9) and 2.3 10 3 3.3 10 3 cDNA molecules in colon (n = 18), per 10 6 molecules of bactin cDNA (Fig. 1) .
Localisation of PPARg in human pancreatic tissue.
Expression of PPARg in pancreatic tissue was studied next by immunohistochemistry on human pancreatic sections. Simple immunolabelling of PPARg using the same antibody as used for the western blots confirmed that this nuclear receptor was highly expressed in islets (Fig. 2) . Immunolabelling on adjacent sections of glucagon, insulin and somatostatin, hormones that are specific to alpha, beta and delta cells, respectively, showed the presence of PPARg in all three cell types of human islets (Fig. 2) . Expression of PPARg in beta cells was confirmed by double immunolabelling of PPARg and insulin in the same pancreatic section (Fig. 2) . 
Discussion
In patients with Type II (non-insulin-dependent) diabetes mellitus, thiazolidinediones reduce peripheral insulin resistance, but also seem to improve the pattern of insulin secretion. Various rodent studies suggest that thiazolidinediones could exert a direct effect on beta cell morphology and function, by preventing pancreatic islet hyperplasia and beta cell hypertrophy, by restoring beta cell granulation and the intra-islet distribution pattern of the alpha and beta cell and by lowering islet fat content [4, 5] . In this study, we show that PPARg is expressed in normal human pancreatic islets at the mRNA and protein levels. Although documented in various tissues such as adipose tissue, large and small intestine, haematopoietic cells, kidney, liver and muscle [1] , the expression of PPARg has to date never been described in the human pancreas. Using RT-PCR we have shown the expression of PPARg mRNA in human islet preparations, corroborating its previous detection in the rodent pancreas [10] . Although PPARg mRNA was detected in all subjects studied, marked differences in expression were observed by RT-competitive PCR reflecting the highly variable characteristics of the organ donors. Western blot studies showed the consistent presence of high concentrations of PPARg protein in all islet preparations. Important differences in protein concentrations and mRNA expressions of PPARg were observed between WAT and islet preparations. This discrepancy is most likely attributed to a combination of several factors including the presence of enzymes influencing the stability of mRNA and protein and the difference in sensitivity of each of the techniques used. We confirmed by immunochemistry that PPARg was preferentially localised in the endocrine islets within the pancreas. No difference was noted between the three endocrine cell types studied (alpha, beta and delta) which all co-expressed PPARg. When exposing human islet preparations obtained from these non-diabetic donors to various concentrations of rosiglitazone, we did not observe any effect on basal nor stimulated insulin secretion. These results confirm those obtained in the lean wild-type ( + / + ) Zucker diabetic fatty rats [5] . Nevertheless, when studying islets of obese homozygous (fa/fa) Zucker diabetic fatty rats, these authors showed that thiazolidinediones restore the beta-cell insulin secretion pattern by lowering islet fat content [5] , an effect potentially mediated by PPARg.
We found the transcription and expression of PPARg in human islet endocrine cells to be consistent. These findings further highlight the connection between PPARg and glucose homeostasis [6] and support the hypothesis of a direct influence of thiazolidinediones on pancreatic beta cell homeostasis explaining their action on the insulin secretion pattern in diabetic patients. 
